Alamar Biosciences, Inc. IPO - What You Need to Know

Thinking about the Alamar Biosciences IPO? Biotech can be complex, so here is a plain-English breakdown to help you decide if this investment fits your goals.

1. What does this company do?

Alamar aims to catch diseases like cancer, Alzheimer’s, and heart conditions long before doctors usually can. They created a platform called "NULISA."

Think of this technology as a super-sensitive magnifying glass for blood samples. It detects tiny proteins that act as early warning signs for disease. While other tools struggle to see these proteins, Alamar’s "capture and release" method filters out background noise. This allows them to spot markers at extremely low levels. Currently, they help researchers find new medical insights, with a goal to become a standard tool for hospital labs.

2. How do they make money?

Alamar uses a "razor and blade" business model. They sell their "ARGO HT" testing machines and the specialized kits required to run each test.

Growth is strong. They brought in $74.2 million in 2025, nearly triple their $25.1 million in 2024. Their "installed base"—the number of machines in labs—grew from 36 to 102 in one year. Even better, the revenue per machine jumped from $357,000 to $529,000. This shows that researchers are actively using the machines for high-volume testing.

3. Are they profitable?

Not yet. Like many young biotech firms, they spend heavily on research and expanding their sales team. They lost $29.8 million in 2025. However, this is an improvement from their $47.1 million loss in 2024. As revenue grows, their costs are becoming more efficient. They are currently spending cash to build the business, betting that recurring revenue from testing kits will eventually outpace their operating costs.

4. What will they do with the IPO money?

Alamar expects to raise over $130 million. They plan to use this cash to:

• Research & Development: Create new tests for more diseases and speed up their ARGO HT system.
• Sales & Marketing: Hire more sales staff and scientists to support labs in North America and Europe.
• Clinical Goals: Fund the trials needed to secure FDA approval for their first diagnostic tests by 2027.

5. What are the main risks?

• Competition: They face established companies with deeper pockets and stronger industry ties.
• Customer Funding: Their customers rely on government grants and venture capital. If that funding dries up, Alamar’s sales could drop.
• Regulation: They must meet strict FDA standards. Any delay in their 2027 approval goal could hurt their stock price.
• Ongoing Losses: There is no guarantee they will become profitable. They may need to issue more shares in the future, which would reduce your ownership percentage.

6. Where will it trade?

They have applied to list on the Nasdaq under the ticker symbol “ALMR.”

Final Thought: Is this for you?

Investing in an IPO like Alamar is a bet on the future of medical diagnostics. You are essentially deciding if you believe their NULISA platform will become the industry standard for early disease detection. If you are comfortable with the risks of a company that is still burning cash to fuel rapid growth, this might be worth a closer look. If you prefer companies that are already turning a profit, you may want to wait and see how they progress toward their 2027 FDA goals.

Disclaimer: I am an AI, not a financial advisor. IPOs are high-risk. Stock prices can be volatile. Never invest money you cannot afford to lose, and always read the company’s official prospectus on the SEC website before buying.